GDTC Stock Summary and Trading Ideas (Cytomed Therapeutics Limited - | NASDAQ:GDTC)

CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.

Cytomed Therapeutics Limited - trades on the NASDAQ stock market under the symbol GDTC.

As of January 23, 2026, GDTC stock price climbed to $1.00 with 9,695 million shares trading.

GDTC has a beta of 0.05, meaning it tends to be less sensitive to market movements. GDTC has a correlation of 0.00 to the broad based SPY ETF.

GDTC has a market cap of $11.73 million. This is considered a Sub-Micro Cap stock.

GDTC has underperformed the market in the last year with a price return of -60.8% while the SPY ETF gained +14.9%. GDTC has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -62.7% and -23.7%, respectively, while the SPY returned +3.5% and 0.0%, respectively.

GDTC support price is $.87 and resistance is $1.03 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GDTC shares will trade within this expected range on the day.